Comprehensive Lipid Panel: HDL, LDL, Triglycerides and the Functional Targets Standard Ranges Miss

The standard lipid panel is one of the most frequently ordered blood tests in Australia. It is bulk-billed under Medicare, runs on virtually every analyser in every pathology network, and underpins most primary-care cardiovascular risk conversations. Yet the reference ranges printed on the report were calibrated to identify people at high short-term risk of a coronary event, not to describe the lipid profile of someone optimising long-term arterial health.

The gap between those two goals is widening. Mendelian randomisation studies have consistently shown that the relationship between atherogenic lipoproteins and cardiovascular disease is linear and lifelong (Ference et al., 2017, European Heart Journal). The earlier and lower exposure begins, the lower lifetime event risk — and the threshold for "benefit" extends well below what most Australian labs flag as abnormal. Functional and preventive-cardiology frameworks have responded by tightening targets, particularly for triglycerides, non-HDL cholesterol, and the triglyceride-to-HDL ratio.

This article walks through each component of the panel, contrasts conventional reference ranges with functional optimal targets, and explains why LDL-C alone is an incomplete picture of cardiovascular risk.

What the Lipid Panel Actually Measures

A conventional Australian lipid panel reports four or five values. Each describes a different aspect of how the body packages and transports lipids in the blood.

Total Cholesterol

Total cholesterol is the sum of cholesterol carried in every lipoprotein class — HDL, LDL, IDL, VLDL and Lp(a). On its own it is a blunt marker. Two people with identical total cholesterol can have radically different particle compositions and risk profiles. Its main use today is as an input into derived values such as non-HDL cholesterol.

HDL Cholesterol

HDL-C is the cholesterol carried in high-density lipoprotein particles. HDL participates in reverse cholesterol transport, returning cholesterol from peripheral tissues to the liver. Higher HDL-C is generally associated with lower cardiovascular event rates in observational data, although Mendelian randomisation has been unable to confirm a causal protective effect of pharmacologically raising HDL-C (Voight et al., 2012, The Lancet). HDL function appears to matter more than the cholesterol concentration alone.

LDL Cholesterol — Calculated vs Direct

Most Australian labs report calculated LDL-C using the Friedewald equation:

LDL-C = Total Cholesterol − HDL-C − (Triglycerides ÷ 2.2)

The equation is fast and cheap but degrades at triglycerides above roughly 2.3 mmol/L and at low LDL values, where it can understate true LDL-C by 10–20%. Newer estimating equations (Martin/Hopkins, Sampson) correct most of this error. Direct LDL-C measurement avoids the calculation entirely and is increasingly used when triglycerides are elevated, when fasting samples are not available, or when LDL-C is already low.

For most people with triglycerides under 2.0 mmol/L the calculated value is acceptable. Above that, request direct LDL-C or non-HDL cholesterol instead.

Triglycerides

Triglycerides reflect the amount of fat circulating in chylomicrons and VLDL particles. They are highly responsive to recent meals, alcohol, and insulin status. Fasting triglycerides above 1.7 mmol/L are an early signal of insulin resistance and excess hepatic VLDL secretion, often appearing years before fasting glucose or HbA1c drift upward.

Non-HDL Cholesterol

Non-HDL = Total Cholesterol − HDL-C. It captures the cholesterol carried in every atherogenic particle class — LDL, IDL, VLDL, chylomicron remnants, and Lp(a) — in a single number. Non-HDL is more strongly associated with cardiovascular events than LDL-C in people with elevated triglycerides or insulin resistance (Boekholdt et al., 2012, JAMA). It costs nothing extra because it is derived from values already on the panel.

VLDL Cholesterol

VLDL-C is usually estimated as Triglycerides ÷ 2.2 (in mmol/L). It approximates the cholesterol carried in very-low-density lipoprotein particles produced by the liver. VLDL particles are atherogenic in their own right and their remnants drive much of the residual risk seen in metabolic syndrome.

Conventional Ranges vs Functional Optimal Targets

Australian pathology reports typically flag values using ranges aligned with the National Heart Foundation's primary prevention thresholds. These were chosen to identify people who likely need pharmacological intervention, not to define a low-risk lipid profile.

| Marker | Standard Australian Reference | Functional Optimal Target | |---|---|---| | Total cholesterol | <5.5 mmol/L | <4.5 mmol/L | | HDL-C (men) | >1.0 mmol/L | >1.3 mmol/L | | HDL-C (women) | >1.3 mmol/L | >1.5 mmol/L | | LDL-C (primary prevention) | <3.5 mmol/L | <2.6 mmol/L | | LDL-C (high risk) | <1.8 mmol/L | <1.4 mmol/L | | Triglycerides | <2.0 mmol/L | <1.0 mmol/L | | Non-HDL cholesterol | <4.0 mmol/L | <2.6 mmol/L | | Total cholesterol : HDL ratio | <4.5 | <3.5 |

The functional targets are not arbitrary. LDL-C below 2.6 mmol/L is the threshold at which most large statin trials begin showing event-rate plateaus, and triglycerides under 1.0 mmol/L correspond to the population-average value seen in metabolically healthy adults without insulin resistance. The gap between the "normal" column and the "optimal" column is where most modifiable cardiovascular risk now sits in Australia.

The Triglyceride-to-HDL Ratio

The ratio of fasting triglycerides to HDL-C (both in mmol/L) is one of the most under-used numbers on the panel. It correlates tightly with insulin resistance, LDL particle size, and the presence of small dense LDL — the most atherogenic LDL subspecies (McLaughlin et al., 2003, Annals of Internal Medicine).

Approximate interpretation in Australian units (mmol/L):

• <0.87 — favourable, large-buoyant LDL predominant pattern
• 0.87–1.74 — intermediate, mixed pattern
• >1.74 — unfavourable, small-dense LDL pattern likely

A person can present with an apparently normal LDL-C of 3.0 mmol/L, a triglyceride of 2.0 and HDL of 1.0, giving a ratio of 2.0. That profile is consistent with insulin resistance and small-dense LDL despite an LDL-C that would not be flagged. Conversely, a person with LDL-C of 3.5, triglycerides of 0.7 and HDL of 1.8 has a ratio of 0.39 — a fundamentally lower-risk pattern despite the higher LDL number.

The ratio is free, fast, and travels well across labs because it is unit-cancelling.

Why LDL-C Alone Is Incomplete

LDL-C measures the concentration of cholesterol carried inside LDL particles. It does not measure the number of particles, and it cannot see Lp(a) at all unless specifically requested. Two failure modes follow.

Discordance with particle number. When triglycerides are high and HDL is low, LDL particles tend to be small and dense. Each particle carries less cholesterol, so LDL-C can look acceptable while particle count is high. Apolipoprotein B (ApoB) — measured directly rather than calculated — counts every atherogenic particle, including VLDL and IDL remnants, and outperforms LDL-C in head-to-head prediction studies (Sniderman et al., 2019, JAMA Cardiology). The functional position discussed in this guide on ApoB and the case for measuring particle number is that ApoB should be ordered alongside, or in place of, calculated LDL-C whenever the cost and access allow.

Invisibility of Lp(a). Lipoprotein(a) is a genetically determined LDL-like particle with an attached apolipoprotein(a) tail. It is atherogenic, prothrombotic, and present at clinically meaningful levels in roughly one in five adults. It is not captured in LDL-C, not modified by lifestyle, and not requested on the standard panel. A one-off measurement is enough to characterise lifetime exposure — covered in detail in the Lp(a) genetic risk explainer.

A complete lipid assessment in 2026 is best thought of as: standard panel + ApoB + a single lifetime Lp(a). The standard panel describes lipid transport; ApoB and Lp(a) describe the particles doing the damage.

What Moves Each Marker

Lipid values respond to a mix of dietary, metabolic, hormonal, and genetic inputs. Knowing what shifts each marker helps interpret unexpected results.

HDL-C rises with regular aerobic exercise, monounsaturated fat intake, moderate alcohol, and oestrogen exposure. It falls with anabolic androgen use, smoking, very-low-fat diets, untreated hypothyroidism, and chronic systemic inflammation.

LDL-C rises with saturated fat intake (especially in ApoE4 carriers), dietary cholesterol in hyper-responders, weight loss in a subset of lean-mass-hyper-responder phenotypes on very-low-carbohydrate diets, hypothyroidism, cholestasis, and certain genetic variants (familial hypercholesterolaemia). It falls with reduced saturated fat, soluble fibre, plant sterols, weight loss in most phenotypes, and pharmacotherapy.

Triglycerides are the most modifiable marker on the panel. They rise sharply with refined carbohydrate and fructose intake, alcohol, insulin resistance, untreated hypothyroidism, oestrogen therapy, and recent food intake. They fall with carbohydrate restriction, omega-3 EPA/DHA intake at gram-level doses, weight loss, aerobic exercise, and treatment of insulin resistance.

Non-HDL and the Tg:HDL ratio track the underlying metabolic state. Improvement in insulin sensitivity tends to move all components in a favourable direction simultaneously. The metabolic-vascular coupling underlying this pattern — and its downstream consequences for cerebrovascular health — is explored in the research summary on metabolic dysfunction and dementia risk.

Genetic contribution is substantial. Familial hypercholesterolaemia (LDLR, APOB, PCSK9 variants) drives LDL-C from birth. ApoE genotype shifts dietary responsiveness. Lp(a) is set by the LPA gene and barely moves with anything. A lipid panel that does not respond to lifestyle change is not necessarily a failure of adherence — it may be a signal to look at genetics and ApoB.

How to Interpret Your Own Results

A practical reading order for an Australian lipid report:

1. Check fasting status. Most labs accept non-fasting samples now, but triglycerides above 2.0 mmol/L on a non-fasting sample are harder to interpret. Re-test fasting if borderline.
2. Read triglycerides first. They are the fastest-moving marker and the clearest signal of metabolic state. Above 1.7 mmol/L, suspect insulin resistance.
3. Calculate the Tg:HDL ratio. A ratio above 1.74 suggests small-dense LDL and warrants ApoB measurement regardless of how the LDL-C looks.
4. Read non-HDL cholesterol. If the lab does not report it, subtract HDL-C from total cholesterol. This is a better single-number risk indicator than LDL-C when triglycerides are elevated.
5. Read LDL-C in context. Use the functional target appropriate to baseline risk. If triglycerides are over 2.3 mmol/L, treat calculated LDL-C as an underestimate and request direct LDL-C or ApoB.
6. Add ApoB and a one-time Lp(a) to characterise particle number and lifetime genetic exposure. Both are available privately in Australia and increasingly through Medicare for higher-risk patients.

Trend matters more than any single result. Three measurements over six to twelve months reveal whether values are stable, drifting, or responding to changes.

Key Takeaways

• The standard Australian lipid panel reports total cholesterol, HDL-C, LDL-C, triglycerides, and ratios. Non-HDL cholesterol can be derived from values already present.
• Conventional reference ranges identify high short-term risk. Functional optimal targets — triglycerides under 1.0 mmol/L, non-HDL under 2.6 mmol/L, LDL-C under 2.6 mmol/L for primary prevention — reflect the lipid profile of metabolically healthy adults.
• The triglyceride-to-HDL ratio is one of the most informative free numbers on the panel. Above 1.74 mmol/L:mmol/L it points to insulin resistance and small-dense LDL.
• LDL-C measures cholesterol concentration, not particle number, and cannot see Lp(a). ApoB and a one-time Lp(a) close both gaps and increasingly define the modern lipid workup.
• Triglycerides are the most responsive marker to lifestyle change. HDL-C and LDL-C move more slowly. Lp(a) does not move with lifestyle at all.
• Genetic factors set the baseline. If a lipid panel does not respond to consistent lifestyle change over six months, look at ApoE, LDLR, and LPA rather than assume non-adherence.